Breaking News


Effects of ustekinumab on quality of life and sexual difficulties in psoriasis patients


A post-hoc analysis of two placebo-controlled, randomized controlled trials (N = 1,996) were conducted to analyze the quality of life (QoL) and sexual difficulties in patients receiving ustekinumab for psoriasis. QoL was assessed by means of the Dermatology Life Quality Index (DLQI) and question 9 was used to probe sexual difficulties. Impaired sexual function was defined as "very much" or "a lot" of difficulties. At baseline, 22.6% of patients reported impaired sexual function and had a mean DLQI score of 12.0. At week 12, impaired sexual function had decreased to 2.7% in the ustekinumab group, with no change in the placebo group (P < 0.001). Ustekinumab patients had a greater improvement ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list